A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial

British Journal of Cancer

Volumn 108, Issue 4, 2013, Pages 866-872

  Provenzano, E ^a,b,c   Vallier, A L ^d   Champ, R ^d   Walland, K ^d   Bowden, S ^e   Grier, A ^e   Fenwick, N ^e   Abraham, J ^a,b   Iddawela, M ^a,b,c,f   Caldas, C ^a,b,f   Hiller, L ^g   Dunn, J ^g   Earl, H M ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NIHR Cambridge Biomedical Research Centre   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

breast cancer; clinical trials; histopathology; neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; PACLITAXEL;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PROGNOSIS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84875213813     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.547     Document Type: Review

References (38)

1. AJCC (2010) Breast. In Cancer Staging Handbook from the AJCC Cancer Staging Manual, Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) 7th edn, pp 419-460.
2. Bear HD (2010) Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy. Surg Oncol Clin N Am 19: 607-626.
3. Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A (2011) International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer. Cremona, Italy (2010). J Natl Cancer Inst Monogr 2011: 147-151.
4. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545.
5. Buzdar AU (2007) Preoperative chemotherapy treatment of breast cancer-a review. Cancer 110: 2394-2407.
6. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML (2005) American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97: 1137-1142.
7. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16: 223-228.
8. Chollet P, Amat S, Belembaogo E, Cure H, de Latour M, Dauplat J, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Penault-Llorca F (2003) Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 89: 1185-1191.
9. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobagyi GN, Gonzalez-Angulo AM (2008) Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13: 6-15.
10. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22: 515-523.
11. Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE (2009) Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res 11(Suppl 3): S15.
12. Earl H, Vallier A-L, Hillier L, Fenwick N, Iddawela M, Hughes-Davies L, Provenzano E, McAdam K, Hickish T, Caldas C (2009 Neo-tAnGo: A neoadjuvant randomised phase III trial of epirubicin/cyclophosphamide (EC) and paclitaxel (T)±gemcitabine (G) in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint-pathological complete response (pCR). J Clin Oncol 27(Suppl 15abstract 522; poster presentation.
13. Generali D, Symmans WF, Berruti A, Fox SB (2011) Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2011: 99-102.
14. Gounaris I, Britton P, Taylor K, Wallis M, Hiller L, Vallier A-L, Provenzano E, Iddawela M, Earl H, Sinnatamby R (2011) Accuracy of uni-dimensional and volumetric measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 127(2): 459-469.
15. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23: 9304-9311.
16. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F (2009) Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 250: 558-566.
17. Ismail A, Azzawi K, Farouhi P, Earl H, Malata CM (2010) Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction: a retrospective comparison. Plast Reconstr Surg 126(1): 1-11.
18. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE (2006) Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 94: 358-362.
19. Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, Sahin AA (2009) Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer 115: 1605-1612.
20. Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, Bear HD, Caldwell CB, Walker AP, Mikkelson WM, Stauffer JS, Robidoux A, Theoret H, Soran A, Fisher B, Wickerham DL, Wolmark N (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23: 2694-2702.
21. Marchio C, Sapino A (2011) The pathologic complete response open question in primary therapy. J Natl Cancer Inst Monogr 2011: 86-90.
22. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L (2007) Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25: 2650-2655.
23. Newman EA, Sabel MS, Nees AV, Schott A, Diehl KM, Cimmino VM, Chang AE, Kleer C, Hayes DF, Newman LA (2007) Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 14: 2946-2952.
24. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12: 320-327.
25. Oh JL, Nguyen G, Whitman GJ, Hunt KK, Yu TK, Woodward WA, Tereffe W, Strom EA, Perkins GH, Buchholz TA (2007) Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 110: 2420-2427.
26. Papa MZ, Zippel D, Kaufman B, Shimon-Paluch S, Yosepovich A, Oberman B, Sadetzki S (2008) Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol 98: 403-406.
27. Penault-Llorca F, Abrial C, Raoelfils I, Cayre A, Mouret-Reynier MA, Leheurteur M, Durando X, Achard JL, Gimbergues P, Chollet P (2008) Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 39: 1221-1228.
28. Pinder SE, Provenzano E, Earl H, Ellis IO (2007) Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 50: 409-417.
29. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26: 778-785.
30. Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20: 1304-1310.
31. Sahoo S, Lester SC (2009) Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 133: 633-642.
32. Sakakibara M, Nagashima T, Kadowaki M, Onai Y, Fujimori T, Yokomizo J, Suzuki H, Fushimi K, Nakatani Y, Miyazaki M (2009) Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol 16: 2470-2478.
33. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297-306.
34. Shimazu K, Noguchi S (2011) Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer. Surg Today 41: 311-316.
35. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466.
36. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25: 4414-4422.
37. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxeldoxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100: 542-551.
38. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96-102.